Buy & Sell Huntington Bancshares Incorporated (HBAN) – Huntington Bancshares Incorporated Price Today
Aura AI Summary
Key Stats
- $34.89BMarket Cap
- FinancialsSector
- -10.02%3M Drawdown
- -Enterprise Value
- 3.6%Dividend Yield
- 17% Buy | 83% SellTrading Activity
- 46 daysTypical Hold Time
Huntington Bancshares Incorporated (HBAN) is currently valued at a market capitalization of $34.89B. Over the past 52 weeks, Huntington Bancshares Incorporated has traded between a low of $15.02 and a high of $19.27, highlighting its annual price range. Over the past three months, Huntington Bancshares Incorporated has recorded a drawdown of -10.02%, reflecting recent price volatility. Huntington Bancshares Incorporated offers a dividend yield of 3.6%, with the most recent dividend of $0.16 paid on 18 Mar 26. On average, investors hold Huntington Bancshares Incorporated for approximately 46 days, indicating typical investor behavior on the platform.
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Most Recent News
Fire engulfs Medline warehouse, causing inventory loss and short-term margin impact.
A fire destroyed Medline's 1 million-square-foot medical equipment warehouse in Tracy, California, affecting about 4% of its U.S. warehouse space. The blaze caused inventory losses and disrupted operations, creating short-term margin pressure as the ...

SpaceX prioritizes growth over profits, following Amazon's strategy to build future value.
SpaceX is choosing to focus on long-term growth rather than immediate profitability, similar to Amazon's approach in its early years. Experts say SpaceX could be profitable now if it reduced spending on projects like Starship and AI infrastructure, b...

New data show Lyell's ronde-cel CAR T-cell therapy is safe and effective for large B-cell lymphoma.
Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and ...
